Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 1/20 | 0.54 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.48 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.48 |
| ▸ | RORC | P51449 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.46 |
| ▸ | STS | P08842 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13876978 | 0.90 | KDM4E (0.56) | KDM4EPKMGPR119USP30STS | |
| SCHEMBL29126588 | 0.88 | GPR119 (0.47) | NAMPTSLC5A1SLC5A2KDM4EPKM | |
| SCHEMBL21618375 | 0.88 | GPR119 (0.48) | NAMPTSLC5A1SLC5A2GPR119NR1H2 | |
| SCHEMBL3443787 | 0.87 | CHEK2 (0.56) | KDM4EPKMUSP30ALOX5APFEN1 | |
| SCHEMBL3443784 | 0.87 | CHEK2 (0.56) | KDM4EPKMUSP30ALOX5APFEN1 | |
| SCHEMBL23693081 | 0.86 | GPR119 (0.48) | NAMPTSLC5A1SLC5A2GPR119NR1H2 | |
| SCHEMBL3249170 | 0.86 | KDM4E (0.61) | KDM4EPKMGPR119STS | |
| SCHEMBL15300717 | 0.86 | SLC5A1 (0.47) | NAMPTSLC5A1SLC5A2RORCGPR119 | |
| SCHEMBL30098766 | 0.86 | NAMPT (0.45) | NAMPTSLC5A1SLC5A2KDM4EPKM | |
| Hydrochloric Acid SCHEMBL28882165 | 0.85 | NAMPT (0.44) | NAMPTSLC5A1SLC5A2KDM4EPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4590673-A1 | FLUORESCENT PROBES FOR MAGL | F. Hoffmann-La Roche AG (CH) | 2025-07-30 | — | — | EP | disclosed |
| WO-2024061853-A1 | FLUORESCENT PROBES FOR MAGL | F. HOFFMANN-LA ROCHE AG (CH) | 2024-03-28 | — | — | WO | disclosed |
| EP-2616465-B1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2015-11-04 | — | — | EP | disclosed |
| US-20150025057-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2015-01-22 | — | — | US | disclosed |
| US-8895733-B2 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-11-25 | — | — | US | disclosed |
| US-20140051676-A1 | Triazine-oxadiazoles | NOVARTIS AG (CH) | 2014-02-20 | — | — | US | disclosed |
| EP-2616465-A1 | TRIAZINE-OXADIAZOLES | Novartis AG (CH) | 2013-07-24 | — | — | EP | disclosed |
| WO-2012035023-A1 | TRIAZINE-OXADIAZOLES | NOVARTIS AG (CH) | 2012-03-22 | — | — | WO | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| US-20080027035-A1 | Dpp-Iv Inhibitors | GRAFFINITY PHARMACEUTICALS AG (DE) | 2008-01-31 | — | — | US | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| EP-1613304-B1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS CH (CH) | 2007-09-12 | — | — | EP | disclosed |
| CN-1905868-A | DPP-IV inhibitors | GRAFFINITY PHARMACEUTICALS AG (CH) | 2007-01-31 | — | — | CN | disclosed |
| EP-1613304-A1 | DPP-IV INHIBITORS | Graffinity Pharmaceuticals Aktiengesellschaft (DE) | 2006-01-11 | — | — | EP | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
| WO-2005056003-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) GMBH (CH) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080027035-A1 | Dpp-Iv Inhibitors | DPP4, DPP7, DPP3 | NAMPT 873/4885SLC5A1 10/4885SLC5A2 12/4885 |
| US-20150025057-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | NAMPT 2748/4885SLC5A1 1457/4885SLC5A2 1115/4885 |
| US-20140051676-A1 | Triazine-oxadiazoles | OPRK1, OPRD1, OPRL1 | NAMPT 2748/4885SLC5A1 1457/4885SLC5A2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.